Summary & Overview
CPT 0420U: Cxbladder Detect Urine Molecular Assay for Bladder Cancer Risk
CPT code 0420U is a Proprietary Laboratory Analyses (PLA) code assigned exclusively to the Cxbladder Detect urine test from Pacific Edge Diagnostics USA LTD. The assay measures five-gene mRNA expression and six single-nucleotide polymorphisms across two genes, using an algorithmic model to report an individualized risk of urothelial (bladder) cancer for symptomatic patients. As a PLA code, 0420U identifies a single manufacturer's test and supports billing for a specialized molecular diagnostic service offered in clinical laboratories and outpatient specimen collection settings.
Key payers examined in national coverage discussions include Aetna, Blue Cross Blue Shield plans, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical utilization scenarios for symptomatic patients, payer coverage landscape, and where to locate relevant coding and manufacturer information. The publication summarizes benchmarking and policy considerations relevant to proprietary molecular diagnostics without making clinical recommendations. Data not provided in the input includes specific payer policies, reimbursement amounts, and associated ICD-10 diagnoses; those items are noted as unavailable and should be obtained from payer policy documents or the manufacturer when needed.
Billing Code Overview
CPT code 0420U is a Proprietary Laboratory Analyses (PLA) code specific to a single commercial test: Cxbladder Detect from Pacific Edge Diagnostics USA LTD. The test is a urine-based molecular assay that measures mRNA expression of five genes and analyzes six single-nucleotide polymorphisms (SNPs) in two genes, applying an algorithmic analysis to report a risk score for urothelial (bladder) cancer in symptomatic patients.
Service type: Laboratory — Proprietary molecular diagnostic test
Typical site of service: Clinical laboratory or outpatient specimen collection site (urine specimen)
Data not available in the input for payers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 64-year-old male presents to urology clinic with painless gross hematuria and intermittent dysuria. He has a 40–pack-year smoking history and a prior history of recurrent urinary tract infections. After initial evaluation including history, physical exam, and urinalysis, the urologist orders a urine-based molecular test, 0420U (Cxbladder Detect, Pacific Edge Diagnostics USA LTD), to assess mRNA expression of five genes and six SNPs to estimate the risk of urothelial (bladder) cancer. The specimen is collected as a voided urine sample at the clinic, labeled with patient identifiers, and shipped to the performing laboratory per manufacturer instructions. The lab performs RNA extraction, mRNA expression analysis, SNP genotyping, and algorithmic risk scoring. Results are returned to the ordering urologist within the lab’s reporting timeframe to guide the need for further evaluation such as cystoscopy, urine cytology, or imaging. Typical sites of service include outpatient urology clinics, ambulatory surgical centers for specimen collection, and the performing reference laboratory where analysis is completed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default, no modifier reported | Use when no special modifier applies to the claim for the laboratory test |